Annexon Announces Pricing of $125 0 Million Underwritten Public Offering of Common Stock tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Annexon Inc. (ANNX), a clinical-stage biopharmaceutical company focused on inflammatory-related diseases, reported Wednesday positive results from the Phase 1 trial of ANX1502, its oral small molecule inhibitor of the classical complement pathway.
Annexon has an average rating of Outperform and price targets ranging from $4 to $30, according to analysts polled by Capital IQ.
Price: 3.75, Change: +0.87, Percent Change: +30.21
.
On Wednesday, Annexon Inc ANNX reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of…